InvestorsHub Logo
Followers 0
Posts 56
Boards Moderated 0
Alias Born 12/12/2014

Re: dr_lowenstein post# 31255

Tuesday, 06/30/2015 6:44:42 PM

Tuesday, June 30, 2015 6:44:42 PM

Post# of 48316
Amazing, as this is one area I fully agree with you. While ONCS management has done a lot of good in other areas there is no getting around the fact that they made mistakes when it comes to this pivotal trial. Anyone arguing otherwise is just blinding themselves to reality. By working on too many things it distracted them from the key task at hand. They made assumptions that caused unnecessary delay in the pivotal trial because they focused too much of their time away from that which was most critical. As a long shareholder it is disappointing, but it is being addressed and the trial should start soon.

You can see the slow response and recognition of the problem in the position they opened to hire a Manager of Regulatory Affairs. This should have been done back in December. However, this is typical of companies at this stage. Sometimes you need to live with the bad as well as the good. Resources and $$ could have been applied to help ensure that UCSF was on track. While UCSF is going to conduct the study, it is more critical to ONCS than UCSF. This means both constant follow up and supplying resources to help with key tasks and review of critical materials.

I am sure IR is getting an earful on this topic. At this point we know there are no critical issues, but they do need to complete the process. Maybe now, they will do it with more of a sense of urgency.